Abstract
Importance Management of long-term consequences after acute COVID-19 in people with multiple sclerosis and related disorders (pwMSRD) is challenging due to overlapping clinical presentations. There have been limited investigations of post-COVID sequelae in pwMSRD.
Objective We assessed whether pwMSRD were more susceptible to post-COVID sequelae when compared to controls.
Design This cross-sectional study leveraged a multi-center cohort of pwMSRD and controls.
Setting A one-time web-based survey was conducted between August and December 2022.
Participants Out of the 2,156 participants who consented, the analysis included 1,972 after excluding 184 due to missing data.
Main Exposure Diagnosis of MSRD.
Main Outcomes and Measures We surveyed 71 symptoms that emerged at least 1 month after the initial acute COVID-19 and were either new onset or worsening from the pre-COVID baseline. We assessed whether each participant experienced (1) ≥1 new symptom, (2) ≥1 worsening symptom from baseline.
Results The study included 969 pwMSRD (799 [82.5%] women, mean age 51.8 [SD 12.1] years) and 1,003 controls (796 [79.4%] women, mean age 45.2 [SD 10.3] years). 613 pwMSRD (63.5%) and 614 controls (61.2%) experienced acute COVID-19. Compared to controls, pwMSRD had higher odds of developing a new symptom (OR=1.55; 95%CI=1.22-1.98; p<.01) and experiencing a worsening symptom from baseline (OR=3.39; 95%CI=2.64-4.36; p<.01). PwMSRD were more likely to develop new symptoms involving the pulmonary as well as head, eyes, ears, nose, and throat systems, and have worsening systemic, musculoskeletal, and neuropsychiatric symptoms from baseline. Acute COVID-19 severity mediated >20% of the association between MSRD diagnosis and post-COVID sequelae. In the subgroup of pwMS, having post-COVID sequelae was associated with worse functional disability.
Conclusions and Relevance Compared to controls, pwMSRD experienced an increased risk of post-COVID sequelae involving multiple organ systems. Post-COVID sequelae was associated with greater disability in pwMS. The findings highlighted the importance of recognizing and managing long-term symptoms following acute COVID-19 in this vulnerable population.
Key Points Question: Are people with multiple sclerosis and related disorders (pwMSRD) more susceptible to post-COVID sequelae?
Findings: In this cross-sectional study that included 969 patients and 1,003 controls, pwMSRD had higher odds of experiencing post-COVID sequelae than controls after acute COVID-19. The association was mediated by the severity of acute COVID-19. Post-COVID symptoms, both new and worsening symptoms from baseline, were associated with worse neurological disability.
Meaning: These findings highlight the importance of recognizing and effectively managing post-COVID sequelae in pwMSRD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is supported in part by NINDS R01NS098023 and NINDS R01NS124882
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of Pittsburgh gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Share co-first authorship
Abbreviations
- aOR
- adjusted odds ratio
- CNS
- central nervous system
- CCI
- Charlson comorbidity index
- DMT
- disease-modifying therapy
- HEENT
- head, eyes, ears, nose, and throat
- MOGAD
- myelin oligodendrocyte glycoprotein antibody-associated disease
- MS
- multiple sclerosis
- MSRD
- multiple sclerosis and related disorders
- MSReCOV
- Multiple Sclerosis Resilience to COVID-19 Collaborative
- MSRS-R
- multiple sclerosis rating scale, revised
- NID
- neuroimmunological disorders
- NMOSD
- neuromyelitis optica spectrum disorder
- PDDS
- patient determined disease steps
- PRO
- patient-reported outcomes
- PROMIS
- Patient-reported outcomes measurement information system
- pwMS
- people with multiple sclerosis
- pwMSRD
- people with multiple sclerosis and related disorders
- REDCap
- Research Electronic Data Capture
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.